Canada (CA)

Analysis of surfactant-associated bacteria in the sea surface microlayer using deoxyribonucleic acid sequencing and synthetic aperture radar (2020) Parks G, Dean CW, Kluge JA, Soloviev AV, Shivji M, Tartar A, Howe KL, et al. Journal article Phenotypic spectrum and transcriptomic profile associated with germline variants in TRAF7 (2020) Castilla-Vallmanya L, Selmer KK, Dimartino C, Rabionet R, Blanco-Sanchez B, Yang S, Reijnders MRF, et al. Journal article Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis (2020) Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZ, Thuny F, Zlotoff DA, et al. Journal article Inferring soot morphology through multi-angle light scattering using an artificial neural network (2020) Talebi Moghaddam S, Bauer F, Huber F, Will S, Daun KJ Journal article, Review article Assessment of individual tumor buds using keratin immunohistochemistry: moderate interobserver agreement suggests a role for machine learning (2020) Bokhorst JM, Blank A, Lugli A, Zlobec I, Dawson H, Vieth M, Rijstenberg LL, et al. Journal article Correction to: Assessment of individual tumor buds using keratin immunohistochemistry: moderate interobserver agreement suggests a role for machine learning (Modern Pathology, (2020), 33, 5, (825-833), 10.1038/s41379-019-0434-2) (2020) Bokhorst JM, Blank A, Lugli A, Zlobec I, Dawson H, Vieth M, Rijstenberg LL, et al. Journal article, Erratum A quasi-Hopf algebra for the triplet vertex operator algebra (2020) Creutzig T, Gainutdinov AM, Runkel I Journal article Cardiac Computed Tomography for Atrial Fibrillation Patients Undergoing Ablation: Implications for the Prediction of Early Recurrence (2020) Ebersberger U, Bernard ML, Schoepf UJ, Wince WB, Litwin SE, Wang Y, Blanke P, et al. Journal article Predictors of progression in systemic sclerosis patients with interstitial lung disease (2020) Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler J, et al. Journal article, Review article Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution